Tenax Therapeutics (TENX) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
XBiotech (XBIT) has outperformed Tenax Therapeutics (TENX) over the past year, losing 18.2% versus a loss of 76.2%. Over five years, XBIT leads with a -83.3% price change compared with -99.9% for TENX. Tenax Therapeutics is the larger company by market cap ($69.6 million vs $67.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TENX | XBIT |
|---|---|---|
| Share price | $1.86 | $2.20 |
| Market cap | $69.61M | $67.07M |
| 1-day change | -2.62% | +0.46% |
| YTD return | -84.74% | -7.95% |
| 1-year return | -76.25% | -18.22% |
| 5-year return | -99.93% | -83.35% |
| Forward P/E | — | 16.92 |
| EPS (TTM) | $-1.48 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.40 | $3.44 |
| 52-week low | $1.31 | $2.09 |
| Distance from 52-week high | -90.41% | -36.05% |
| Analyst consensus | none | — |
| Avg. price target upside | +575.27% | — |
| Average volume | 5.46M | 39.91K |
| Shares outstanding | 37.42M | 30.49M |
| Employees | 14 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XBIT has outperformed TENX by 58.0 percentage points over the past year.
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
TENX vs XBIT FAQ
Which is bigger, Tenax Therapeutics or XBiotech?
Tenax Therapeutics (TENX) is larger, with a market capitalization of $69.61M compared with $67.07M for XBiotech (XBIT).
Which stock has performed better over the past year, TENX or XBIT?
XBIT returned -18.22% over the past 12 months, compared with -76.25% for TENX (price return, excluding dividends). Past performance does not predict future results.
Are Tenax Therapeutics and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.